1415098-72-4

Upstream product

• 15186-48-8 2,3-isopropylidene-glyceraldehyde 
• 1415098-65-5 N-{(S)-1-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]allyl}-3-buten-1-amine 
• 1415098-68-8 N-benzyloxycarbonyl-N-{(S)-1-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]allyl}-3-buten-1-amine 

Downstream Products

• 1415098-87-1 (S)-1-[(S)-1-benzyloxycarbonyl-1,2,5,6-tetrahydropyridin-2-yl]-1,2-ethanediol 
• 1415099-03-4 (2S,3R,4S)-1-benzyloxycarbonyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]piperidine-3,4-diol 
• 1415098-82-6 (1S,2R,6R)-3-benzyloxycarbonyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]-7-oxa-3-azabicyclo[4.1.0]heptane 
• 1415098-77-9 (1R,2R,6S)-3-benzyloxycarbonyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]-7-oxa-3-azabicyclo[4.1.0]heptane 

Relevant academic research and scientific papers

Stereoselective synthesis and biological evaluation of d-fagomine, d-3-epi-fagomine and d-3,4-epi-fagomine analogs from d-glyceraldehyde acetonide as a common building block

The stereoselective synthesis of d-fagomine, d-3-epi-fagomine, and d-3-epi-fagomine analogs starting from readily available d-glyceraldehyde acetonide has been achieved. The synthesis involves diastereoselective anti-vinylation of its homoallylimine, ring-closing metathesis, and stereoselective epoxidation followed by regioselective ring-opening or stereoselective dihydroxylation. The lack of a strong activity as glycosidase inhibitors of these compounds could be advantageous for their therapeutic use as chaperones.